Pre-emptive pharmacogenetic testing in the acute hospital setting: a cross-sectional study
These findings demonstrate the potential scale, and potential clinical utility, of pharmacogenetic testing as an intervention, highlighting the need to develop infrastructure to support healthcare professionals make use of this emerging tool.
Authors
- Katherine Payne (ORCID: https://orcid.org/0000-0002-3938-4350)
- John McDermott (ORCID: https://orcid.org/0000-0002-5220-8837)
- Kerry A. Burke (ORCID: https://orcid.org/0009-0002-8678-8865)
- James O’Sullivan (ORCID: https://orcid.org/0009-0002-3425-6058)
- Andrew Stevens (ORCID: https://orcid.org/0000-0003-2079-3397)
- Amy Ingham
- Videha Sharma (ORCID: https://orcid.org/0000-0001-7640-1239)
- Paul Wilson (ORCID: https://orcid.org/0000-0002-2657-5780)
- Tania Syed
- Rhys Beynon
- Nicholas S. Greaves (ORCID: https://orcid.org/0000-0002-5646-9364)
- Daniel Akam
- William G. Newman (ORCID: https://orcid.org/0000-0002-6382-4678)
- Stuart Wright (ORCID: https://orcid.org/0000-0002-4064-7998)
- Selman Mirza
- Neil Fullerton
- Aleina Alex
- Nicola Godfrey
- Aghogho Odudu
Institutions
- Manchester Academic Health Science Centre (GB)
- Manchester Royal Infirmary (GB)
- University of Manchester (GB)
- Manchester University NHS Foundation Trust (GB)
- St Mary's Hospital (GB)
- Evolutionary Genomics (United States) (US)
- St. Mary’s Hospital (ZA)
- Primary Health Care (QA)
- Genomics (United Kingdom) (GB)
- Manchester University (US)
Publication Details
- Journal
- QJM
- Published
- 2024-10-17
- DOI
- https://doi.org/10.1093/qjmed/hcae200
- Citations
- 6
- Primary Topic
- Pharmaceutical studies and practices
- Type
- article
- Field-Weighted Citation Impact
- 6.66
Funders
- Wellcome Trust
- National Institute for Health and Care Research
- Manchester Biomedical Research Centre